M1 Aesthetics AG
Stock
Stock
ISIN: DE000A289VV1
Ticker: HAEK
DE000A289VV1
HAEK
Price
Price
CHART BY
Frequently asked questions
What is M1 Aesthetics AG's market capitalization?
The market capitalization of M1 Aesthetics AG is $79.47M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for M1 Aesthetics AG?
M1 Aesthetics AG's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $2.131. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for M1 Aesthetics AG's stock?
Currently, 1 analysts cover M1 Aesthetics AG's stock, with a consensus target price of $38.13. Analyst ratings provide insights into the stock's expected performance.
What is M1 Aesthetics AG's revenue over the trailing twelve months?
Over the trailing twelve months, M1 Aesthetics AG reported a revenue of $301.37M.
What is the EBITDA for M1 Aesthetics AG?
M1 Aesthetics AG's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $11.93M. EBITDA measures the company's overall financial performance.
What is the free cash flow of M1 Aesthetics AG?
M1 Aesthetics AG has a free cash flow of $12.75M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
What is the free float of M1 Aesthetics AG's shares?
The free float of M1 Aesthetics AG is 1.65M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $79.47M
- EPS (TTM)
- $2.131
- Free Float
- 1.65M
- Revenue (TTM)
- $301.37M
- EBITDA (TTM)
- $11.93M
- Free Cashflow (TTM)
- $12.75M
Pricing
- 1D span
- $14.88$15.59
- 52W span
- $9.519$15.85
Analyst Ratings
The price target is $38.13 and the stock is covered by 1 analysts.
Buy
1
Hold
0
Sell
0
Information
Haemato AG engages in the pharmaceutical industry. It focuses on growth markets of patent-free, and patented medicinal products in the insurance-financed market. Its portfolio include therapies for cancer, HIV, rheumatology, and other chronic diseases, and products for the privately financed market for aesthetic treatments. It operates through the Lifestyle and Aesthetics, and Specially Pharma segments. The company was founded on May 10, 1993 and is headquartered in Schönefeld, Germany.
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- DE000A289VV1
- Primary Ticker
- HAEK
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet